Stocks making the biggest moves premarket: eBay, Norwegian Cruise Line, Coinbase & more

Premarket trading was driven by a $55.5 billion unsolicited GameStop offer for eBay, sending eBay up nearly 9% while GameStop fell more than 2.5%. Norwegian Cruise Line dropped 5.5% on a Q1 earnings beat but weak guidance, Axsome Therapeutics fell more than 3.5% on a wider-than-expected loss, and Tyson Foods rose over 2.5% on better-than-expected quarterly results. Energy and crypto names rallied on higher oil prices and progress on crypto legislation, while AMD slipped nearly 1% after an HSBC downgrade.

Analysis

The cleanest takeaway is that this tape is rewarding names with either credible scarcity value or explicit linkage to a narrative macro shock, while punishing anything exposed to cash-flow surprise risk or weak forward visibility. The eBay move is less about the bid itself and more about signaling optionality: once a strategic buyer is public, the market starts pricing a control premium even if the deal is unlikely to clear. That creates a tactical squeeze in the target, but the acquirer’s stock weakness suggests investors see execution risk, financing drag, or strategic distraction rather than synergy value.

Energy is functioning as a geopolitical hedge, but the second-order effect is that higher crude pressures the exact sectors with the weakest pricing power: travel, consumer discretionary, and leveraged leisure operators. Norwegian’s guide-down is a reminder that in a fuel shock, demand elasticity and margin compression matter more than headline occupancy; if oil stays elevated for weeks, expect the market to de-rate cruise, airline, and lower-end consumer names before it fully reflects in consensus estimates. The winners are not just producers — mid-cap E&Ps with cleaner balance sheets should outperform integrateds on a relative basis because the market will favor direct oil beta over downstream complexity.

The semiconductor/photonics reaction is still underappreciated. AI networking is increasingly about optical bottlenecks, so a bullish read-through for Lumentum and Coherent is valid, but the more important implication is that capital is rotating toward infrastructure picks-and-shovels, not just compute. If that theme persists, the trade can broaden into test equipment, networking components, and other supply-chain names that benefit from higher optical content and data-center capex reprioritization.

Crypto is getting a policy multiple expansion, but this remains a headline-driven trade until legislative text is clearer. The market is likely pricing a reduction in regulatory overhang rather than immediate revenue upside, which means the first fade risk is if the bill’s final language narrows economics for exchanges or stablecoin issuers. Biotechnology remains the opposite: results-driven downside with limited near-term narrative support, so weak earnings prints are likely to be sold harder in a market that is still rewarding visible catalysts.

Key Decisions for Investors

• Trade the geopolitical oil shock via long APA/OXY/FANG against short NCLH over the next 1-3 weeks; the pair captures the fuel-cost shock while avoiding outright beta, with cruise margin compression likely to show up before producer upside is fully reflected.
• Buy LITE and COHR on dips as a 1-2 month AI infrastructure basket; target continued multiple expansion if optical spending remains a priority, but use tight stops because the move is sentiment-led and can reverse quickly if broader AI capex cools.
• Consider a tactical long EBAY / short GME pair for 2-4 weeks only if the acquisition narrative persists; the risk/reward favors the target on optionality, while the acquirer’s downside should widen if investors conclude the bid is a distraction or non-serious.
• Avoid chasing GEMI on the crypto policy headline; if you want exposure, prefer higher-quality liquid proxies like COIN over the next 1-2 months, since stablecoin/platform complexity creates more downside if legislative details disappoint.
• Short AXSM on any rebound into the next several sessions or sell call spreads; in small/mid-cap biotech, an earnings miss of this type can re-rate the stock for weeks as investors demand stronger evidence before re-anchoring estimates.